Solasia Pharma KK (FRA:9SO) ROCE %: -70.02% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:9SO Solasia Pharma KK FRA:9SO
50 GF Score
Price €0.12
GF Value €0.01
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Solasia Pharma KK ROCE %?

Solasia Pharma KK FRA:9SO +4.31% 50 ROCE % is -70.02% as of Mar. 2026. GuruFocus rates FRA:9SO with a GF Score™ of 50/100 and a GF Value™ of €0.01 (Significantly Overvalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Solasia Pharma KK's annualized ROCE % for the quarter that ended in Mar. 2026 was -70.02%.

Solasia Pharma KK  (FRA:9SO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Solasia Pharma KK ROCE % Related Terms

Solasia Pharma KK ROCE % Historical Data

* Premium members only.

The historical data trend for Solasia Pharma KK's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solasia Pharma KK ROCE % Chart

Solasia Pharma KK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -75.36 -87.16 -46.03 -127.80 -59.80

Solasia Pharma KK Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -120.26 -86.04 0.00 0.00 -70.02
FRA:9SO
50GF Score
Solasia Pharma KK FRA:9SO
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Solasia Pharma KK ROCE % Calculation

Solasia Pharma KK's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-4.721/( ( (8.419 - 1.745) + (11.382 - 2.268) )/ 2 )
=-4.721/( (6.674+9.114)/ 2 )
=-4.721/7.894
=-59.80 %

Solasia Pharma KK's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-6.584/( ( (11.382 - 2.268) + (10.859 - 1.167) )/ 2 )
=-6.584/( ( 9.114 + 9.692 )/ 2 )
=-6.584/9.403
=-70.02 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -70.02% mean?
Solasia Pharma KK (FRA:9SO) has a ROCE % of -70.02% as of Mar. 2026.
Is Solasia Pharma KK's ROCE % too high?
Solasia Pharma KK's current ROCE % is -70.02%. Overall, Solasia Pharma KK has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Solasia Pharma KK's ROCE % compare to ZTS and UTHR?
Solasia Pharma KK's ROCE % of -70.02% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.04, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solasia Pharma KK's current ROCE % is -70.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solasia Pharma KK stock overvalued right now?
Based on GuruFocus' analysis, Solasia Pharma KK (FRA:9SO) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.01, compared to a current price of €0.12 — trading 1110% above its estimated fair value. The current ROCE % is -70.02%. Solasia Pharma KK's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Solasia Pharma KK (FRA:9SO), the current ROCE % is -70.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Solasia Pharma KK (FRA:9SO) Overvalued in 2026?

Based on GuruFocus' analysis, Solasia Pharma KK stock appears to be overvalued. The current stock price of €0.12 is trading 1110% above its estimated GF Value™ of €0.01. GuruFocus considers Solasia Pharma KK to be Significantly Overvalued.

Key valuation signals for FRA:9SO:

  • ROCE %: -70.02%
  • GF Value™: €0.01 vs. price of €0.12 (1110% above fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the FRA:9SO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Solasia Pharma KK Business Description

Other Exchanges 4597:Japan
Address 2-1-1 Shiba Park, 4th Floor, Sumitomo Real Estate Shiba Park Tower, Minato-ku, Tokyo, JPN, 105-0011
Solasia Pharma KK develops and distributes pharmaceuticals and medical devices relating to malignant tumors.
50GF Score

Get the complete analysis for FRA:9SO

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.12
Price
€0.01
GF Value